Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy [clinicaltrials:NCT00002449]
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy [clinicaltrials:NCT00002449]
Bio2RDF identifier
NCT00002449
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002449
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... ple
with HIV infection.
brief title [clinicaltrials_vocabulary:brief-title]
Safety and Effectiveness of L2 ...... nts Receiving Anti-HIV Therapy
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
This study takes place ...... for access to
L2-7001.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Anti-HIV Agents
CD4 Lymphocyte Count
Dose-Response Relationship, Drug
Injections, Subcutaneous
Interleukin-2
Pharmacokinetics
Recombinant Proteins
Viral Load
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2005-06-23T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002449
official title [clinicaltrials_vocabulary:official-title]
A Bridging Dose-Escalation Stu ...... e Antiretroviral Therapy (ART)
org study id [clinicaltrials_vocabulary:org-study-id]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
CS-MM-9901
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-08-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2001-07-01T00:00:00Z
identifier
clinicaltrials:NCT00002449
title
Safety and Effectiveness of L2 ...... nts Receiving Anti-HIV Therapy
@en
type
label
Safety and Effectiveness of L2 ...... y [clinicaltrials:NCT00002449]
@en